stockrow
Saturday 7 November 2026
Export MGX’s income statement to Excel — free account
Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.2 million, down 51.8% from fiscal 2024.
- Revenue
- −103.0%
- EPS
- −35.2%
- Free cash flow
- +7.98%
Quarter to June 2026, against a year earlier
0.70
0.03
−4.11%
Follow MGX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 17 | 45 | 52 | 25 | 14 | +219.1% | 5 | 7 | 4 | (43.8%) | |
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | (21) | (41) | (60) | (84) | (88) | (94) | +42.3% | ||||||
| EBT margin, % | — | — | — | — | — | (8,823.87) | (238.51) | (134.57) | (159.81) | (348.77) | (690.60) | +8,475.1 pt | ||||||
| Net income | — | — | — | — | — | (21) | (44) | (68) | (78) | (88) | (93) | +42.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.07 | 5.06 | 13.14 | 1.58 | 0.68 | 0.36 | +73.6% | |||||
| Earnings | — | — | — | — | — | (6.58) | (12.82) | (20.05) | (2.36) | (2.36) | (2.49) | (22.6%) | ||||||
| Cash flow | — | — | — | — | — | 7.45 | 8.74 | (26.85) | (3.30) | (2.39) | (2.27) | n/m | ||||||
| Capex | — | — | — | — | — | (0.89) | (4.11) | (2.88) | (0.09) | (0.01) | (0.01) | (64.3%) | ||||||
| Free cash flow | — | — | — | — | — | 6.55 | 4.63 | (29.73) | (3.40) | (2.40) | (2.28) | n/m | ||||||
| Book value | — | — | — | — | — | 13.49 | 79.90 | 63.19 | 7.11 | 4.26 | 2.99 | (25.0%) | ||||||
| Shares, m | — | — | — | — | — | 3 | 3 | 3 | 33 | 37 | 37 | +83.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.78 | 0.78 | 0.78 | 2.28 | 2.39 | 1.94 | 1.4 | ||||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.51 | 0.38 | 0.23 | 0.2 | ||||||
| EV/Sales | — | — | — | — | — | (4.60) | (4.60) | (4.60) | (1.89) | (2.78) | (4.72) | (3.7) | ||||||
| EV/FCF | — | — | — | — | — | 2.03 | 2.03 | 2.03 | 0.88 | 0.78 | 0.75 | 1.6 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 24 | 30 | (91) | (109) | (89) | (85) | n/m | |||||
| Capex | — | — | — | — | — | (3) | (14) | (10) | (3) | (1) | 0 | (34.4%) | ||||||
| Free cash flow | — | — | — | — | — | 21 | 16 | (101) | (112) | (89) | (86) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 84 | 318 | 209 | 221 | 143 | 97 | +14.2% | |||||
| Net debt | — | — | — | — | — | (78) | (362) | (271) | (248) | (161) | (121) | +19.9% | ||||||
| Shareholders’ equity | — | — | — | — | — | 44 | 272 | 215 | 235 | 159 | 113 | +37.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (15.67) | (17.52) | (22.64) | (32.20) | (41.91) | (32.2) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 81.50 | 65.00 | (157.26) | (44.67) | (60.61) | (44.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 223 | 236 | 202 | 119 | — | (18.9%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.08 | 0.19 | 0.26 | 0.21 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Metagenomi Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EDSA Edesa Biotech, Inc. | $28.8M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $28.6M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| BCTX BRIACELL THERAP | $28.6M | — (loss-making) | — | — | n/m | +26.73% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $28.2M | — (loss-making) | — (loss-making) | +287.18% (above 0%: growing) | n/m | +105.91% (above 0%: growing) | 100.00% | (762.98%) | Compare |
| MGX Metagenomi Therapeutics, Inc. | $27.6M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | |
| PLRZ Polyrizon Ltd. | $27.5M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| ACET Adicet Bio, Inc. | $27.3M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $26.0M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABVC ABVC BioPharma, Inc. | $25.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $27.8M | — | — | +287.18% | — | +25.83% | 50.00% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
12.50%
Bayer HealthCare LLC
10.80%
Brian C. Thomas, Ph.D.
8.00%
Entities affiliated with Sozo Ventures
5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement